Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

Abstract: A computer-implemented method for determining failures in laboratory equipment comprising: a) receiving a desired probability of false rejection ({hacek over (P)}fr) and a desired error detection rate ({hacek over (E)}D), such as a desired probability of error detection ({hacek over (P)}ed), relating to one or more QC levels (J) of quality control (QC) samples to be processed by the equipment; b) setting a number of runs (R) to one; c) calculating an error detection rate (ÊD) based at least partially on R; d) determining if ÊD is below {hacek over (E)}D, and if so: increase R by one, and repeat steps c) to d), and if not: define a rule for determining failures in the laboratory equipment based, at least partially, on R; e) receiving or collecting standardized QC results; f) applying the rule defined in step d) to the standardized QC results; g) determining failures in the equipment, if the standardized QC results comply with the rule.

Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein TIMP-1 (tissue inhibitor of metalloproteinase 1) as a marker molecule in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual, the method involving measuring TIMP-1 in the sample. Measurement of TIMP-1 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention is directed to a method for determining whether a patient suffering from cancer will be responsive to a treatment with a 5-Fluoro-Uracil and/or 5-Fluoro-Uracil analogs. Specifically, the invention relates to methods of determining the expression levels of certain mRNAs to determine responsiveness to drug treatment.

Abstract: A solid phase with at least one test area is described which contains reagents for the detection of at least one analyte in a sample, wherein the solid phase additionally comprises at least one control area for the detection of interfering reactions.

Abstract: A solid phase with at least one test area is described which contains reagents for the detection of at least one analyte in a sample, wherein the solid phase additionally comprises at least one control area for the detection of interfering reactions.

Abstract: The present invention relates to a method and a device for metering liquids, wherein the volume of a droplet of a sample liquid is determined by means of optical measuring. The liquid to be metered is brought into contact with a transfer element so that a droplet adheres to the transfer element. The transfer element and the liquid adhering thereto are illuminated from one or several directions and the resulting images are displayed on an optical sensor. The liquid volume is determined on the basis of these images. Metering is accomplished by transferring the liquid volume adhering to the transfer element into an analysis vessel.

Abstract: Apparatus for the detection of a phase boundary (10) in a transparent measuring tube (9), in particular of a liquid level in a rising tube (11) (LLD, Liquid Level Detector). The rising tube (11) is illuminated by an illumination device (15) and the light passing through the rising tube (11) is received by a light reception device (17) which converts it into signals dependent on the spatial distribution of the light intensity. A data processing unit (7) is used for processing the signals from the light reception device (17) into information on the height of the liquid level (10) in the rising tube (11).

Abstract: A method for the analysis of a medical sample, particularly a body fluid, with the aid of an analyzing instrument, in which a test fluid, which contains an aliquot part of the sample and reagents, is in an optical cuvette and the temperature of the test fluid is determined in the cuvette. In order to determine the temperature of the test fluid directly and without contact, in a temperature calibration step the optical absorption of a calibrator fluid is determined at various temperatures at at least two wavelengths within the NIR range in order to obtain a calibration data set relating to the temperature-dependency of the optical absorption. In a temperature-measuring step the optical absorption of a test fluid of unknown temperature is measured at the same wavelengths and its temperature is determined by comparison of the absorption data obtained in the measuring step with the calibration data set.